InvestorNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) Regains Compliance with Nasdaq Minimum Bid Price Requirement
March 14, 2024
180 Life Sciences (NASDAQ: ATNF) today announced that it received a letter on March 13, 2024, from the Nasdaq Stock Market LLC indicating that the company has regained full compliance with the minimum bid price for continued listing on the Nasdaq pursuant to Nasdaq Listing Rule 5550(a)(2) (“Minimum Bid Price Requirement”). As detailed in the […]
InvestorNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) Plans 1-for-19 Reverse Stock Split to Regain NASDAQ Compliance
February 26, 2024
180 Life Sciences (NASDAQ: ATNF), a clinical-stage biotechnology company, will conduct a reverse stock split of its outstanding shares of common stock. The ratio of the reverse stock split, which is slated to go into effect on Feb. 28 with market open, will be 1-for-19. According to the announcement, the reverse stock split, which was […]
InvestorNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) Announces Engagement of Alliance Global Partners
December 4, 2023
180 Life Sciences (NASDAQ: ATNF) today announced it has engaged A.G.P./Alliance Global Partners as financial advisor to explore and evaluate strategic alternatives to enhance shareholder value. According to the announcement, potential alternatives that may be explored or evaluated by 180 Life Sciences as part of this process include, but are not limited to, an acquisition, […]
InvestorNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) Officials, Board to Review of Strategic Alternatives
November 28, 2023
180 Life Sciences (NASDAQ: ATNF), a clinical-stage biotechnology company, and its board of directors has initiated a process to evaluate potential strategic alternatives. The goal of the process is to identify ways to unlock and maximize shareholder value. According to the announcement, company officials are working with financial and legal advisors as they consider a […]
InvestorNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) Closes on $3M Public Offering
August 15, 2023
180 Life Sciences (NASDAQ: ATNF), a clinical-stage biotechnology company, has closed on its previously announced public offering. The offering was comprised of 4,615,385 shares of the company’s common stock (or common stock equivalents in lieu thereof) as well as warrants to purchase up to 4,615,385 shares of common stock at a purchase price per share […]
InvestorNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) Releases Public Offering Pricing, Offering Could Reach $3M
August 10, 2023
180 Life Sciences (NASDAQ: ATNF), a clinical-stage biotechnology company, announced the pricing of its current public offering. The offering consists of up to 4,615,385 shares of the company’s common stock and warrants for purchase at $0.65 per share. According to the announcement, the warrants, which will expire on Oct. 10, 2028, will be immediately exercisable […]
InvestorNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) Enters Agreement for Strategic PK Study
August 7, 2023
180 Life Sciences (NASDAQ: ATNF) today announced its entry into an agreement with Prof. Avi Domb of the Hebrew University, School of Pharmacy, and with Prof. Elyad Davidson, of Hadassah Hospital, to perform a clinical pharmacology (“PK”) study of the uptake of cannabidiol (“CBD”) in a formulation that can be delivered as an oral pill. […]
InvestorNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) Issues Update on Regulatory Approval Process for Dupuytren’s Disease Treatment
August 3, 2023
180 Life Sciences (NASDAQ: ATNF) is a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain. The company today announced that it has submitted a request to the United Kingdom’s Medicines and Healthcare products Regulatory Agency (“MHRA”) for a follow-up scientific advice meeting where […]
InvestorNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) Announces the Filing of a Provisional Patent Describing the Combination of CBD With GLP-1 Agonists to Suppress Appetite
July 31, 2023
180 Life Sciences (NASDAQ: ATNF), a clinical-stage biotechnology company, today announced the filing of a provisional patent describing the novel combination of cannabidiol (“CBD”), or an analog thereof, with glucagon related peptide-1 (“GLP-1”) agonists to address obesity and weight management. Co-administration of CBD, a known appetite suppressant and antiemetic, might be expected both to limit […]
InvestorNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) Closes on $3M Registered Direct Offering, Concurrent Private Placement
April 11, 2023
180 Life Sciences (NASDAQ: ATNF), a clinical-stage biotechnology company, has closed on its previously announced issuance and sale of 1,570,680 shares of the company’s common stock in a registered direct offering and warrants. The shares were offered at a purchase price of $1.91 in a concurrent private placement, resulting in gross proceeds of an estimated […]
InvestorNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) Announces $3M Registered Direct, Concurrent Private Placement
April 5, 2023
180 Life Sciences (NASDAQ: ATNF), a clinical-stage biotechnology company, today announced its entry into a definitive agreement with a health care-focused U.S. institutional investor. The agreement is for the purchase and sale of 1,570,680 shares of the company’s common stock (or common stock equivalents in lieu thereof) in a registered direct offering and warrants to […]
InvestorNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) to Present at Summer Research Conference
February 27, 2023
180 Life Sciences (NASDAQ: ATNF), a clinical-stage biotechnology company, will be participating at the Gordon Research Conference, which is slated for July 9–14, 2023. The presentation, which is titled “Physiological and Disease Relevance and Underlying Molecular Properties of Collagens,” will be presented by Professor Jagdeep Nanchahal. The conference will be held at Colby-Sawyer College in […]
InvestorNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) Releases Update on Change of Status for Anti-TNF Frozen Shoulder Trial, Receives Patent Notification
February 23, 2023
180 Life Sciences (NASDAQ: ATNF), a clinical-stage biotechnology company, has closed recruitment in England for its anti-TNF frozen shoulder trial. The company had been enrolling men and women with early-stage frozen shoulder to participate in the study, which was called the Anti-Freaze-F trial. The study was designed to evaluate whether an intra-articular injection of anti-TNF (Adalimumab) […]
InvestorNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) Medical Advisory Board Chair Coauthors Review of Early Stage Dupuytren’s Disease Treatment
January 25, 2023
180 Life Sciences (NASDAQ: ATNF), a clinical-stage biotechnology company, has announced the publication of a review written by Professor Jagdeep Nanchahal, chair of ATNF’s medical advisory board; the review was also written by a colleague of Nanchahal’s from the University of Oxford. Titled “Treatments for early stage Dupuytren’s disease: An evidence-based approach,” the article was […]
InvestorNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) Engages Kinexum for Assistance in MAA Submission
January 17, 2023
180 Life Sciences (NASDAQ: ATNF) today announced its engagement of Kinexum, a strategic advisory firm, to support the company in submitting a Marketing Authorisation Application (“MAA”) for adalimumab to treat progressive early-stage Dupuytren’s disease. According to the announcement, the MAA will be submitted to the United Kingdom’s Medicines and Healthcare products Regulatory Agency (“MHRA” or […]
InvestorNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) Is Notified by NASDAQ Exchange of Full Compliance
January 5, 2023
180 Life Sciences (NASDAQ: ATNF), a clinical-stage biotechnology company, has regained full compliance with NASDAQ minimum-bid price requirements. The company received a letter from the NASDAQ Stock Market LLC providing notification of the change in status; the letter was dated Jan. 4, 2023. According to the letter, the exchange determined that the closing bid price […]
InvestorNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) Announces Review on Molecular Basis of Dupuytren’s Disease
January 4, 2023
180 Life Sciences (NASDAQ: ATNF) today announced the publication of a review entitled “Dupuytren’s disease: a localized and accessible human fibrotic disorder” in the journal Trends in Molecular Medicine. In the article, the authors at the University of Oxford, led by Professor Jagdeep Nanchahal, chairman of the medical advisory board of 180 Life Sciences, describe […]
InvestorNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) Releases Shareholder Letter with Corporate Update
December 29, 2022
180 Life Sciences (NASDAQ: ATNF), a clinical-stage biotechnology company, has released a letter to shareholders; the letter is signed by CEO James Woody. In the letter, Woody notes that the company’s priority continues to be its clinical programs, repurposing anti-tumor necrosis factor (“TNF”) drugs for the treatment of Dupuytren’s disease, frozen shoulder and post-operative delirium. […]
InvestorNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) Closes on Registered Direct Offering for $6M
December 27, 2022
180 Life Sciences (NASDAQ: ATNF), a clinical-stage biotechnology company, has closed on its previously announced registered direct offering. The offering, which was with a single healthcare-focused U.S. institutional investor, was comprised of 1,714,286 shares of the company’s common stock (or common stock equivalents in lieu thereof) and warrants to purchase up to 2,571,429 shares of […]
InvestorNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) Enters into Registered Direct Offering Agreement for $6M Proceeds
December 21, 2022
180 Life Sciences (NASDAQ: ATNF), a clinical-stage biotechnology company, has entered into a definitive agreement with a single healthcare-focused U.S. institutional investor. The agreement is for a registered direct offering to include the purchase and sale of 1,714,286 shares of the company’s common stock (or common stock equivalents in lieu thereof) and warrants to […]
InvestorNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) Releases Status Update on MHRA Interaction
December 1, 2022
180 Life Sciences (NASDAQ: ATNF), a clinical-stage biotechnology company, is sharing an update on its efforts to seek marketing authorization from Medicines and Healthcare Products Regulatory Agency (MHRA) for Anti-TNF treatment of early-stage Dupuytren’s Contracture. ATNF officials, along with representatives from the company’s regulatory consultants from the United States and the United Kingdom, met with […]
InvestorNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) Announces Participation in Upcoming Biotech Conference
November 21, 2022
180 Life Sciences (NASDAQ: ATNF), a clinical-stage biotechnology company, focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain, will be participating in A.G.P.’s Virtual Biotech Conference. The conference is scheduled for Nov. 30–Dec. 1, 2022. According to the announcement, ATNF president and CEO Dr. James Woody will present […]
InvestorNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) Announces Adalimumab Has Promise as Treatment for Early-Stage Dupuytren’s Disease
November 15, 2022
180 Life Sciences (NASDAQ: ATNF), a clinical-stage biotechnology company, has announced that adalimumab, its anti-TNF treatment, has shown potential to be a cost-effective treatment for people affected by early-stage Dupuytren’s disease. According to the announcement, researchers at Oxford Population Health’s Health Economics Research Centre and the Kennedy Institute of Rheumatology have identified the potential; adalimumab […]
InvestorNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) Issues Letter to Stockholders
September 26, 2022
180 Life Sciences (NASDAQ: ATNF), a clinical-stage biotechnology company, today released a letter to stockholders from its Chief Executive Officer Dr. James Woody. In the letter, Dr. Woody discussed the company’s continued status to remain on track with clinical development plans. “Currently, we have an active clinical development program that includes phase 2a and phase […]
InvestorNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) Enrolls First Patient in Early-Stage Frozen Shoulder Trial
August 22, 2022
180 Life Sciences (NASDAQ: ATNF), a clinical-stage biotechnology company, is noting a significant milestone reached in a key clinical trial designed to evaluate anti-tumor necrosis factor (“TNF”) for patients with early-stage, pain predominant frozen shoulder. The company announced that the first patient has been randomized in the trial, which is funded by UK-based National Institute […]
InvestorNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) Announces Grant Award to the University of Oxford to Conduct Anti-TNF Therapy Trial
July 27, 2022
180 Life Sciences (NASDAQ: ATNF), a clinical-stage biotechnology company, today announced that a team led by researchers at University of Oxford were awarded a grant from the National Institute for Health and Care Research (“NIHR”) in the U.K. to conduct a feasibility trial. The trial will investigate whether anti-tumor necrosis factor (“TNF”) therapy, administered at […]
InvestorNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) Secures $6.5M in Registered Direct Offering
July 21, 2022
180 Life Sciences (NASDAQ: ATNF), a clinical-stage biotechnology company, today announced the closing of its registered direct offering to a single health care-focused U.S. institutional investor. The offering consisted of 6,132,076 shares of the company’s common stock (including common stock equivalents in lieu thereof) and warrants to purchase up to 6,132,076 shares of common stock […]
InvestorNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) Announces $6.5M Registered Direct Offering
July 18, 2022
180 Life Sciences (NASDAQ: ATNF), a clinical-stage biotechnology company, today announced its entry into a definitive agreement with a single health care-focused U.S. institutional investor, for the purchase and sale of 6,132,076 shares of the company’s common stock (or common stock equivalents in lieu thereof) and warrants to purchase up to 6,132,076 shares of common […]
InvestorNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) CEO Issues Letter to Stockholders
June 23, 2022
180 Life Sciences (NASDAQ: ATNF), a clinical-stage biotechnology company, has released a letter to stockholders from its Chief Executive Officer Dr. James Woody. In the letter, Dr. Woody provides an update on the company’s plans for developing a novel therapy for patients with early-stage Dupuytren’s disease, “Our overall aim continues to be to develop new, […]
InvestorNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) Shares Status of Anti-TNF Treatment, Responses from MHRA and FDA
June 15, 2022
180 Life Sciences (NASDAQ: ATNF), a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain, has shared progress status on the company’s anti-TNF treatment, adalimumab, designed to treat early-stage Dupuytren’s disease. The company has reached out to the U.K. Medicines and Healthcare products Regulatory Agency […]
InvestorNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) Initiates Formal Discussions with UK and US Regulatory Authorities Following Promising Dupuytren’s Trial
May 31, 2022
180 Life Sciences (NASDAQ: ATNF) is a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain. The company today announced that, following publication of promising data from a phase 2b Dupuytren’s trial in the June 2022 issues of The Lancet Rheumatology, 180 Life Sciences […]
InvestorNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) Report Positive Results of Dupuytren’s Disease Study
May 2, 2022
180 Life Sciences (NASDAQ: ATNF), a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain, has published the final results of its phase 2b study of patients with Dupuytren’s disease. The results were published in “The Lancet Rheumatology.” According to the announcement, highlights of the report […]
InvestorNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) Announces Scientific Advisory Board
February 17, 2022
180 Life Sciences (NASDAQ: ATNF), a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain, has formed a scientific advisory board (“SAB”). Initial board members include the following: Dr. Raphael Mechoulam from the Hebrew University in Israel; Dr. Kevin Tracey from Hofstra/Horthwell in the United States; […]
InvestorNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) Issues Letter to Shareholders from CEO Dr. James Woody
January 31, 2022
180 Life Sciences (NASDAQ: ATNF), a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain, today released a letter to shareholders from its Chief Executive Officer James Woody, MD, PhD. In the letter, Dr. Woody commented on the company’s current share price, indicating that […]
InvestorNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) Announces Participation in Biotech Showcase 2022 Virtual Conference
December 28, 2021
180 Life Sciences (NASDAQ: ATNF), a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain, will be participating in next year’s Biotech Showcase 2022 Virtual Conference. The online event is scheduled for Jan. 10–12, 2022. As part of the company’s participation, ATNF CEO and president […]
InvestorNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) Announces License Agreement with University of Oxford
December 15, 2021
180 Life Sciences (NASDAQ: ATNF), a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain, has entered into a license agreement with the University of Oxford. The exclusive global agreement outlines planned development and commercialization of HMGB1, a regenerative molecule for promoting liver repair and […]
InvestorNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) Releases Additional Info Regarding Successful Dupuytren Phase 2b Clinical Trial Results
December 6, 2021
180 Life Sciences (NASDAQ: ATNF), a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain, has shared follow-up information regarding its phase 2b clinical trial for Dupuytren’s disease; initial results were announced on Dec. 1, 2021. The study was conducted in partnership with Oxford University. […]
InvestorNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) Co-Founder Presents Keynote Address at 2021 International Dupuytren Symposium
December 1, 2021
180 Life Sciences (NASDAQ: ATNF), a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain, today announced that Professor Jagdeep Nanchahal from the University of Oxford, a co-founder of 180 Life Sciences, presented a keynote address at the 2021 International Dupuytren Symposium on Wednesday, […]
InvestorNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) Receives Grants of New Patents Through Licensing Agreement
November 22, 2021
180 Life Sciences (NASDAQ: ATNF), a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain, is growing its patent portfolio. The company announced that the Yissum Research Development Company of the Hebrew University has received grants of two new patents, one in the United States […]
InvestorNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) Co-Founder to Keynote at 2021 International Dupuytren Symposium
November 18, 2021
180 Life Sciences (NASDAQ: ATNF), a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain, today announced that Professor Jagdeep Nanchahal from the University of Oxford, a co-founder of 180 Life Sciences, will present a keynote address at the 2021 International Dupuytren Symposium. The […]